Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PES1 promotes breast cancer by differentially regulating ERα and ERβ
Long Cheng, … , Xiaojie Xu, Qinong Ye
Long Cheng, … , Xiaojie Xu, Qinong Ye
Published July 23, 2012
Citation Information: J Clin Invest. 2012;122(8):2857-2870. https://doi.org/10.1172/JCI62676.
View: Text | PDF
Research Article

PES1 promotes breast cancer by differentially regulating ERα and ERβ

  • Text
  • PDF
Abstract

The initiation of breast cancer is associated with increased expression of tumor-promoting estrogen receptor α (ERα) protein and decreased expression of tumor-suppressive ERβ protein. However, the mechanism underlying this process is unknown. Here we show that PES1 (also known as Pescadillo), an estrogen-inducible protein that is overexpressed in breast cancer, can regulate the balance between ERα and ERβ. We found that PES1 modulated many estrogen-responsive genes by enhancing the transcriptional activity of ERα while inhibiting transcriptional activity of ERβ. Consistent with this regulation of ERα and ERβ transcriptional activity, PES1 increased the stability of the ERα protein and decreased that of ERβ through the ubiquitin-proteasome pathway, mediated by the carboxyl terminus of Hsc70-interacting protein (CHIP). Moreover, PES1 transformed normal human mammary epithelial cells and was required for estrogen-induced breast tumor growth in nude mice. Further analysis of clinical samples showed that expression of PES1 correlated positively with ERα expression and negatively with ERβ expression and predicted good clinical outcome in breast cancer. Our data demonstrate that PES1 contributes to breast tumor growth through regulating the balance between ERα and ERβ and may be a better target for the development of drugs that selectively regulate ERα and ERβ activities.

Authors

Long Cheng, Jieping Li, Yongjian Han, Jing Lin, Chang Niu, Zhichao Zhou, Bin Yuan, Ke Huang, Jiezhi Li, Kai Jiang, Hao Zhang, Lihua Ding, Xiaojie Xu, Qinong Ye

×

Figure 6

PES1 transforms normal HMECs and is required for estrogen-induced breast carcinogenesis.

Options: View larger image (or click on image) Download as PowerPoint
PES1 transforms normal HMECs and is required for estrogen-induced breast...
(A) Anchorage-dependent growth assays in MCF-7 cells transiently transfected with FLAG-tagged PES1, PES1Δ221–322, or PES1Δ311–415. The transfection efficiency is approximately 30%. Cell viability was assessed at the indicated times. *P < 0.01 versus empty vector on day 4. #P < 0.05, †P < 0.01 versus PES1 on day 4. Immunoblot analysis with anti-FLAG is shown. (B) Anchorage-dependent growth assays in MCF-7 cells stably transfected with PES1 siRNA or PES1 siRNA plus siRNA-resistant PES1. Cells were treated with 10 nM E2 and analyzed as in A. *P < 0.01 versus control siRNA without E2 on day 4. #P < 0.01 versus control siRNA with E2 on day 4. Immunoblot analysis with anti-PES1 is shown. (C) Anchorage-independent growth assays in MCF-7 cells stably transfected as in B. Scale bar: 50 μm. (A–C) Data are shown as mean ± SD of 3 independent experiments. *P < 0.01 versus control siRNA without E2. #P < 0.01 versus control siRNA with E2. (D) Volume of xenograft tumors derived from MCF-7 cells expressing control siRNA or PES1 siRNA. Data are shown as mean ± SD (n = 8 for control siRNA; n = 1 for PES1 siRNA due to absence of visible tumors in the other 7 mice). *P < 0.01 versus control siRNA. Representative tumor tissues were subjected to immunoblot analysis with indicated antibodies. (E) Anchorage-independent growth assays in HMECs infected with recombinant lentivirus carrying GFP or PES1. Scale bar: 50 μm. Immunoblotting with the indicated antibodies is shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts